Holstege was supported by ABOARD, a public-private partnership receiving funding from ZonMw and Health Holland, Topsector Life Sciences and Health, the Hans und Ilse Breuer Stiftung, the Horstingstuit ...

In people with normal cognition, depressive symptoms and amyloid pathology were not associated with each other (OR 1.13, 95% CI 0.90-1.40, P=0.29), reported Julie Oomens, PhD, of Maastricht ...

An increased amyloid-β load is not a benign result of aging; it is associated with lower cognitive performance and poor ...

An artificial intelligence (AI) model developed by Mayo Clinic and Ultromics, Ltd., an AI echocardiography company based in ...

The FDA approved a label update with a new titration schedule for donanemab (Kisunla), an anti-amyloid drug approved to treat ...

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

In this clinical study, 91.7% of individuals with Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio positive results had the presence of amyloid plaques by PET scan or CSF test result, and 97.3 % ...